Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of oral ONO 4641 vs interferon beta-1a in relapsing multiple sclerosis
2013-003126-83Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceralifimod in multiple sclerosis (MS) (3 arms), sponsored by Merck KGaA. Primary endpoint: Proportion of subjects free of qualifying relapse over at least 1 year. Started Feb 2014; status: completed.
02
Drugs
ceralifimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-003126-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003126-83.